Company intelligence / Profile preview
BioGenCell
Netanya, Central District, Israelbiogencell.net ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
BioGenCell has developed a unique, autologous stem cell-based therapy platform for microvascular diseases. Its lead product, BCG101, targets critical limb ischemia (CLI), showing promising first-in-human clinical trial results including wound healing, improved walking ability, pain reduction, and enhanced quality of life one year post-treatment. The company is currently advancing through Phase II clinical trials.
- Therapeutic areas
- Cardiovascular
- Modalities
- Cellular therapiesStem cell therapy (autologous stem cells from patient’s own blood)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Strategic partnership with Laniado Hospital in Netanya, Israel
Beyond the preview
Go deeper on BioGenCell.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioGenCell.